YAP1 and cancer: There are currently no available anti-cancer drugs for clinical practice for the PitNETs, but the inhibition of the downstream effector of the YAP/TAZ (AXL inhibitors and monoclonal CTGF antibodies) have been evaluated in clinical trials in several malignancies [211,212] and could be a therapeutic option for PitNETs in the future.